StockData
Viking Therapeutics, Inc. logo

Viking Therapeutics, Inc. (VKTX) stock

VKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 5/30
$26.17−0.71 (-2.64%)

Close on Nov 18, 2026Market cap $3.34BP/E –Yield –

Viking Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Viking Therapeutics's operating income for the twelve months ending Sep 30, 2026 was -$648.57M. For fiscal 2025 it was -$393.34M. The highest annual figure on record is -$12.00M in fiscal 2015.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$393.34M–
FY2024Dec 31, 2024-$150.92M–
FY2023Dec 31, 2023-$100.83M–
FY2022Dec 31, 2022-$70.36M–
FY2021Dec 31, 2021-$55.68M–
FY2020Dec 31, 2020-$42.66M–
FY2019Dec 31, 2019-$32.69M–
FY2018Dec 31, 2018-$26.16M–
FY2017Dec 31, 2017-$19.07M–
FY2016Dec 31, 2016-$13.85M–
FY2015Dec 31, 2015-$12.00M–
FY2014Dec 31, 2014-$23.47M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$187.11M–
Q2 FY2026Jun 30, 2026-$132.60M–
Q1 FY2026Mar 31, 2026-$164.13M–
Q4 FY2025Dec 31, 2025-$164.74M–
Q3 FY2025Sep 30, 2025-$98.56M–
Q2 FY2025Jun 30, 2025-$74.57M–
Q1 FY2025Mar 31, 2025-$55.47M–
Q4 FY2024Dec 31, 2024-$46.24M–
Q3 FY2024Sep 30, 2024-$36.56M–
Q2 FY2024Jun 30, 2024-$34.05M–
Q1 FY2024Mar 31, 2024-$34.07M–
Q4 FY2023Dec 31, 2023-$29.29M–
Q3 FY2023Sep 30, 2023-$27.27M–
Q2 FY2023Jun 30, 2023-$23.74M–
Q1 FY2023Mar 31, 2023-$20.54M–
Q4 FY2022Dec 31, 2022-$20.28M–
Q3 FY2022Sep 30, 2022-$16.20M–
Q2 FY2022Jun 30, 2022-$17.63M–
Q1 FY2022Mar 31, 2022-$16.25M–
Q4 FY2021Dec 31, 2021-$12.51M–
Q3 FY2021Sep 30, 2021-$13.40M–
Q2 FY2021Jun 30, 2021-$15.54M–
Q1 FY2021Mar 31, 2021-$14.23M–
Q4 FY2020Dec 31, 2020-$11.27M–
Q3 FY2020Sep 30, 2020-$9.84M–
Q2 FY2020Jun 30, 2020-$10.61M–
Q1 FY2020Mar 31, 2020-$10.95M–
Q4 FY2019Dec 31, 2019-$8.87M–
Q3 FY2019Sep 30, 2019-$7.44M–
Q2 FY2019Jun 30, 2019-$9.57M–
Q1 FY2019Mar 31, 2019-$6.81M–
Q4 FY2018Dec 31, 2018-$7.04M–
Q3 FY2018Sep 30, 2018-$7.39M–
Q2 FY2018Jun 30, 2018-$6.93M–
Q1 FY2018Mar 31, 2018-$4.81M–
Q4 FY2017Dec 31, 2017-$4.43M–
Q3 FY2017Sep 30, 2017-$4.69M–
Q2 FY2017Jun 30, 2017-$4.98M–
Q1 FY2017Mar 31, 2017-$4.97M–
Q4 FY2016Dec 31, 2016-$3.74M–

More Viking Therapeutics figures

See a number that looks wrong?